阿戈美拉汀治疗老年卒中后抑郁的临床疗效比较

目的探讨阿戈美拉汀对比度洛西汀治疗老年卒中后抑郁症的临床疗效和不良反应。方法将90例诊断为脑卒中后抑郁的老年患者随机分为2组,研究组使用阿戈美拉汀,对照组使用度洛西汀,治疗12周,采用汉密尔顿抑郁量表(HAMD)和神经功能缺损量表(CSS)、睡眠障碍量表(SDRS)、副反应量表(TESS)评定疗效、功能恢复和不良反应。结果研究组和对照组治疗老年脑卒中后抑郁的HAMD、CSS、SDRS评分无显著性差异,总有效率分别为73.3%和71.1%,差异无统计学意义(P>0.05);TESS显示研究组阿戈美拉汀不良反应少,2组差异有统计学意义(P<0.05)。结论阿戈美拉汀有利于老年脑卒中后抑郁患者改善抑郁症状,促进神经功能康复,提高生活能力,是一种安全有效、不良反应少的抗老年卒中后抑郁药。

Agomelatine for elderly patients with post-srtoke depression

Objective To compare the clinical effect and adverse reactions of agomelatine and duloxetine for poststroke depression in elderly patients.Methods A total of 90 patients with elderly post-stroke depression were randomly divided into 2 groups.The treatment group were treated with agomelatine,while the control group were treated with duloxetine.The course of treatment was 12 weeks.The changes of HAMD,CSS,SDRS and TESS in the 2 groups were compared to determine the efficacy,neurological function and adverse reactions.Results The HAMD,CSS,and SDRS between the treatment group and the control group were not significantly different（P 〈0.05）.The total efficiency was 73.3% and 71.1%; TESS of the treatment group was better than that of the control group with statistically significant difference（P 〈0.05）.Conclusion Agomelatine has the efficacy of improving post-stroke depression symptoms,accelerating neurological functional rehabilitation,promoting activities of daily living it is a safe and effective medicine and have very few adverse reactions for the treatment of post-stroke depression in elderly patients.